United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablet is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate tablets contain calcium acetate.  animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women.  patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] .  maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism.  calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are

United States - English - NLM (National Library of Medicine)

safecor health, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablets, usp are indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. patients with hypercalcemia.

United States - English - NLM (National Library of Medicine)

sandoz inc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate gelcaps is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate gelcaps contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions ( 5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following t

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - calcium gluconate monohydrate (unii: czn0mi5r31) (calcium cation - unii:2m83c4r6zb) - calcium gluconate monohydrate 98 mg in 1 ml - these highlights do not include all the information needed to use calcium gluconate injection safely and effectively. see full prescribing information for calcium gluconate injection.calcium gluconate injection, for intravenous use initial u.s. approval: 1941 calcium gluconate injection is indicationd for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. limitations of use the safety of calcium gluconate injection for long term use has not been established. calcium gluconate injection is contraindicated in: - hypercalcemia - neonates (28 days of age or younger) receiving ceftriaxone [see warnings and precautions (5.2 )] 8.1 pregnancy risk summary limited available data with calcium gluconate injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. there are risks to the mother and the fetus associated with hypocalcemia in pregnancy [see clinical considerations] . the estimated background risk of major birth defects an

Malta - English - Medicines Authority

om pharma s.a. r. da industria, 2, 2610-088 amadora, lisboa, portugal - calcium dobesilate - capsule - calcium dobesilate 500 mg - vasoprotectives

Kenya - English - Pharmacy and Poisons Board

calcium dobesilate monohydrate - hard gelatin capsules - each capsule contains: calcium dobesilate… - calcium dobesilate

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - calcium lactobionate; calcium gluconate - oral solution/suspension - calcium lactobionate mineral-calcium active 24.25 g/100ml; calcium gluconate mineral-calcium-salt active 10.39 g/100ml - nutrition & metabolism - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - calcium supplement

Israel - English - Ministry of Health

medic trim healthcare ltd - calcium gluconate - solution for injection - calcium gluconate 902.5 mg / 10 ml - calcium gluconate - calcium gluconate - all conditions where injectable calcium supplement is indicated.

Israel - English - Ministry of Health

gsk consumer healthcare, israel ltd - calcium (as carbonate); calcium (as lactate gluconate) - tablets effervescent - calcium (as lactate gluconate) 149.7 mg; calcium (as carbonate) 350.3 mg - calcium gluconate - calcium gluconate - oral calcium therapy.

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), magnesium (unii: i38zp9992a) (magnesium - unii:i38zp9992a), boron (unii: n9e3x5056q) (boron - unii:n9e3x5056q), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - calcium carbonate 1342 mg - indications and usage: calcium-folic acid plus d chewable wafers are indicated, in addition to diet, to help satisfy the distinctive nutritional requirements of individuals under the supervision of a physician for the treatment of calcium deficiency, skeletal weakness and osteoporosis. calcium-folic acid plus d chewable wafers supplementation may be beneficial to individuals who have an insufficient dietary intake of the nutrients contained therein. calcium and vitamin d supplementation may be useful in both preventing and treating osteoporosis. vitamin d supplementation may be beneficial to those who are institutionalized and/or have reduced exposure to sunlight. folic acid, vitamin b 6 , and vitamin b 12 , may help reduce the risk of cardiovascular disease by lowering blood levels of homocysteine. if dietary intake of calcium is inadequate, patients currently taking bisphosphonates for treatment of osteoporosis should be instructed to take calcium and vitamin d daily (calcium-folic